The value to patients of reducing lesion severity in plaque psoriasis

Journal of Dermatological Treatment

Volumn 22, Issue 5, 2011, Pages 266-275

  Hauber, A Brett ^a   Gonzalez, Juan Marcos ^a   Schenkel, Brad ^b   Lofland, Jennifer H ^c   Martin, Silas ^c  

^a RTI HEALTH SOLUTIONS   (United States)

^b JOHNSON AND JOHNSON   (United States)

^c CENTOCOR INC   (United States)

Author keywords

conjoint analysis; discrete choice experiment; patient preference; psoriasis; willingness to pay

Indexed keywords

ADULT; ARTICLE; BODY SURFACE; DISEASE SEVERITY; FEMALE; HEALTH CARE COST; HUMAN; INFECTION RISK; INJECTION SITE PAIN; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PSORIASIS VULGARIS; SELF REPORT; TREATMENT RESPONSE;

FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT PREFERENCE; PSORIASIS; QUALITY OF LIFE; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX;

EID: 80053081201     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.3109/09546634.2011.588193     Document Type: Article

References (27)

1. Christophers E. Psoriasis-epidemiology and clinical spectrum. Clin Exp Dermatol 2001;26:314-320.
2. Bhosle MJ, Kulkarni A, Feldman SR, Balkrishnan R. Quality of life in patients with psoriasis. Health Qual Life Outcomes 2006;4:35.
3. Kimball AB, Jacobson C, Weiss S, Vreeland MG, Wu Y. The psychosocial burden of psoriasis. Am J Clin Dermatol 2005;6: 383-392. (Pubitemid 43128290)
4. Choi J, Koo JYM. Quality of life issues in psoriasis. J Am Acad Dermatol 2003;49:S57-S61. (Pubitemid 36951248)
5. Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001;137:280-284. (Pubitemid 32240779)
6. Yu AP, Tang J, Xie J, Wu EQ, Gupta SR, Bao Y, Mulani PM. Economic burden of psoriasis compared to the general population and stratified by disease severity. Curr Med Res Opin 2009;25:2429-2438.
7. Fowler JF, Duh MS, Rovba L, et al. The impact of psoriasis on health care costs and patient work loss. J Am Acad Dermatol 2008;59:772-780.
8. Gardinal I, Ammoury A, Paul C. Moderate to severe psoriasis: from topical to biological treatment. J Eur Acad Dermatol 2009;23:1324-1326.
9. Kalb RE. New treatments and management of the psoriasis patient. JMCM 2008;11:40-44.
10. Ashcroft DM, Li Wan Po A, Griffiths CE. Therapeutic strategies for psoriasis. J Clin Pharm Ther 2000;25:1-10. (Pubitemid 30175546)
11. Tristani-Firouzi, Krueger GG. Efficacy and safety of treatment modalities for psoriasis. Cutis 1998;61:11-21.
12. Sterry W, Barker J, Boehncke WH, et al. Biological therapies in the systemic management of psoriasis: international consensus conference. Br J Dermatol 2004:151(Suppl. 69):3-17. (Pubitemid 39215184)
13. Finlay AY, Coles EC. The effect of severe psoriasis on the quality of life of 369 patients. Br J Dermatol 1995;132: 236-244.
14. Lundberg L, Johannesson M, Silverdahl M, Hermansson C, Lindberg M. Quality of life, health-state utilities and willingness to pay in patients with psoriasis and atopic eczema. Br J Dermatol 1999;141:1067-1075. (Pubitemid 30046197)
15. Delfino M, Holt EW, Taylor CR, Wittenberg E, Qureshi AA. Willingness-to-pay stated preferences for 8 health-related quality-of-life domains in psoriasis: a pilot study. J Am Acad Dermatol 2008;59:439-447.
16. Bridges JFP, Kinter ET, Kidane L, Heinzen RR, McCormick C. Things are looking up since we started listening to patients: trends in the application of conjoint analysis in health 1982-2007. Patient 2009;1:1-10.
17. Ryan M, Farrar S. Using conjoint analysis to elicit preferences in health care. BMJ 2000;320:1530-1533. (Pubitemid 30330316)
18. Huber J, Zwerina K. The importance of utility balance in efficient choice designs. J Mark Res 1996;33:307-317.
19. Dey A. Orthogonal fractional factorial designs. New York: Halstead Press; 1985.
20. Kuhfeld W, Tobias F, Garratt M. Efficient experimental design with marketing research applications. J Mark Res 1994;31:545-557.
21. Train K. Discrete Choice Methods With Simulation. Cambridge: Cambridge University Press; 2003.
22. Train K, Sonnier G. Mixed logit with bounded distributions of correlated partworths. In: Scarpa R, Alberini A, editors. Applications of Simulation Methods in Environmental and Resource Economics. Dordrecht: Springer Publisher; 2005.
23. Hanemann M, Loomis J, Kanninen B. Statistical efficiency of double-bounded dichotomous choice contingent valuation. Am J Agr Econ 1991;73:1255-1263.
24. Unutzer J, Katon WJ, Russo J, Simon G, von Korff M, Kin E, Walker E, Ludman E, Bush T. Willingness to pay for depression treatment in primary care. Psychiatr Serv 2003;54:340-345. (Pubitemid 36753007)
25. Lloyd A, McIntosh E, Price M. The importance of drug adverse effects compared with seizure control for people with epilepsy: a discrete choice experiment. Pharmacoeco-nomics 2005;23:1167-1181. (Pubitemid 41633405)
26. Tuominen R, Azbel M, Hemmila J, Mottonen T. Willingness to pay for improvement of physical function among rheumatoid arthritis patients as measured by Health Assessment Questionnaire. Rheumatol Int 2009 Dec 18 [Epub ahead of print].
27. Chuck A, Adamowicz W, Jacobs P, Ohinmaa A, Dick B, Rashiq S. The willingness to pay for reducing pain and pain-related disability. Value Health 2009;12:498-506.